ClinicalTrials.gg
Not yet recruitingNCT07706855Updated Sep 30, 2026

Safety and Efficacy Study of GKL-006RTU in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS)

A Phase 1/2 interventional study of GKL-006RTU injection and Placebo in ARDS (Acute Respiratory Distress Syndrome), sponsored by Beijing Gene Key Life Technology Co., Ltd. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Beijing Gene Key Life Technology Co., Ltd · Phase 1/2, Interventional, and Treatment

How we know

Updated Sep 30, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This is a Phase I/II, multicenter study designed to evaluate the safety, tolerability, and preliminary efficacy of GKL-006RTU injection in participants with moderate to severe Acute Respiratory Distress Syndrome (ARDS).

The study consists of two parts:

Phase I is a single-arm, open-label study. Eligible participants will receive a single intravenous infusion of GKL-006RTU injection (1 bag or 3 bags, containing approximately 5.0±0.5×10\^8 invariant natural killer T (iNKT) cells per bag) in addition to standard background treatment. The primary objective of this phase is to assess the safety and tolerability of the investigational product.

Phase II is a randomized, double-blind, placebo-controlled study. Based on the results from Phase I, participants will receive GKL-006RTU injection or placebo via intravenous infusion, in addition to standard background treatment. The primary objective of this phase is to evaluate the efficacy of GKL-006RTU injection in treating moderate to severe ARDS.

02

Conditions studied

  • ARDS (Acute Respiratory Distress Syndrome)

Browse trials for

03

In context

Acute Lung Injury

382 studies on the registry are indexed under Acute Lung Injury; 73 are open to participants now.

This study's planned enrollment of 52 is below the median of 60 across 227 interventional studies indexed under Acute Lung Injury.

Browse Acute Lung Injury studies →

Lead sponsor

Beijing Gene Key Life Technology Co., Ltd is the lead sponsor of 7 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged 18 to 80 years (inclusive).
  2. Participants (or their legally authorized representatives, if the participant is unable to provide ) who fully understand the nature of the study, voluntarily sign the informed consent form, and are willing to comply with and complete all study procedures during the study period.
  3. Clinically diagnosed with Acute Respiratory Distress Syndrome (ARDS) according to the diagnostic criteria, with a time from diagnosis to enrollment not exceeding 96 hours.
  4. The etiology of ARDS is confirmed to be infectious.
  5. Received active treatment (including anti-infective therapy and lung-protective ventilation strategies) for at least 24 hours; and arterial blood gas analysis results within 6 hours prior to enrollment support the diagnosis of moderate-to-severe ARDS (defined as Arterial Partial Pressure of Oxygen/Fraction of Inspired Oxygen Ratio (PaO2/FiO2) ≤ 200 mmHg and Positive End-Expiratory Pressure [PEEP] ≥ 5 cmH2O).
  6. Participants and their partners must have no plans for reproduction, sperm donation, or egg donation for at least 6 months after the last dose of study drug, and must voluntarily adopt effective measures deemed appropriate by the investigator.

Exclusion criteria

Exclusion Criteria:

  1. Positive screening for infectious diseases meeting any of the following: a)Active virus infection (defined as [positive Hepatitis B Surface Antigen (HBsAg) or positive Hepatitis B Core Antibody (HBcAb)] with Hepatitis B Virus DNA [HBV-DNA] above the ); b) virus (HCV) infection (defined as positive HCV antibody with HCV-RNA above the upper limit of normal); c) (HIV) infection (defined as positive HIV antibody); d) Syphilis infection (defined as positive Treponema pallidum antibody).
  2. Known immune system dysfunction (e.g., primary immunodeficiency, acquired immunodeficiency) or currently receiving systemic therapy.
  3. Expected survival time of less than 72 hours.
  4. Occurrence of a cerebrovascular or cardiovascular event (unstable angina, congestive heart failure, myocardial infarction, or stroke) within the past 6 months; or severe cardiovascular disease at screening: (NYHA) Functional Classification Class III or higher; uncontrolled myocarditis or valvular disease; hemodynamic instability, severe cardiac dysfunction, malignant arrhythmias, or severe rhythm/conduction abnormalities requiring drug therapy within the past 6 months.
  5. Currently receiving or expected to receive Extracorporeal Membrane Oxygenation (ECMO) during the trial period.
  6. Severe hepatic or renal dysfunction at screening: long-term hemodialysis and known severe renal impairment with an estimated (eGFR) \< 30 mL/min/1.73 m² (calculation method detailed in Appendix 6), currently requiring Continuous Renal Replacement Therapy (CRRT); or moderate to severe liver failure ( score > 12 ).
  7. Severe hematological abnormalities at screening: evidence of bleeding with an (INR) ≥ 2.0; severe anemia ( [Hb] \< 60 g/L); moderate or greater thrombocytopenia ( [PLT] \< 50×10⁹/L); Disseminated Intravascular Coagulation (DIC); leukemia; or other hematological abnormalities deemed unsuitable for enrollment.
  8. Severe end-stage respiratory diseases at screening (e.g., with respiratory failure, pulmonary fibrosis, pulmonary hypertension with right heart failure, etc., excluding ARDS).
  9. History of deep vein thrombosis or pulmonary embolism within 6 months prior to enrollment.
  10. History of solid organ or hematopoietic stem cell transplantation.
  11. Severe cardiopulmonary malformations at screening that significantly affect cardiopulmonary function.
  12. Severe neuropsychiatric disorders (e.g., Alzheimer's disease, schizophrenia).
  13. ARDS caused by other etiologies (e.g., trauma, aspiration).
  14. Pregnant or lactating women.
  15. Cumulative use equivalent to > 400 mg of prednisone within 3 weeks prior to screening.
  16. Known to any component of the product, or a history of severe allergies deemed unsuitable for enrollment by the investigator.
  17. Receipt of cell therapy within 6 months prior to screening.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Phase I: GKL-006RTU injection (1 or 3 Bags)

    A single-arm, open-label dose-escalation study. Dose Level 1: 1 bag of GKL-006RTU injection (25 mL/bag, containing 5.0±0.5×10\^8 iNKT cells). Dose Level 2: 3 bags of RTU injection (25 mL/bag, containing 5.0±0.5×10\^8 iNKT cells per bag). Dose escalation follows the '3+3' design based on dose-limiting toxicities (DLTs) observed within a 28-day safety window. All participants will receive standard of care background therapy as per clinical guidelines, including restrictive fluid management and lung-protective ventilation strategies. Supportive care medications (for example, antibiotics, albumin, diuretics) and organ support will be administered at the investigator's discretion based on individual patient needs.

    Drug: GKL-006RTU injection

  • Experimental
    Phase II: GKL-006RTU Injection

    Participants in this arm will receive the Recommended Phase II Dose of GKL-006RTU injection . This is a randomized, double-blind portion of the study. All participants will receive standard of care background therapy as per clinical guidelines, including restrictive fluid management and lung-protective ventilation strategies. Supportive care medications (for example, antibiotics, albumin, diuretics) and organ support will be administered at the investigator's discretion based on individual patient needs.

    Drug: GKL-006RTU injection

  • Placebo comparator
    Phase II: Placebo

    Participants in this arm will receive matching placebo. They will be randomized in a 1:1 ratio to the GKL-006RTU injection arm. The study is double-blind. All participants will receive standard of care background therapy as per clinical guidelines, including restrictive fluid management and lung-protective ventilation strategies. Supportive care medications (for example, antibiotics, albumin, diuretics) and organ support will be administered at the investigator's discretion based on individual patient needs.

    Drug: Placebo

Interventions

  • DrugGKL-006RTU injection

    iNKT cell injection

  • DrugPlacebo

    Matching placebo for GKL-006RTU injection

06

What researchers measure

Primary outcomes

  1. Phase I: Incidence and Severity of Adverse Events and Serious Adverse Events

    To evaluate the safety and tolerability of GKL-006RTU injection in participants with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS). Safety will be assessed throughout the study duration, from Day 1 to Day 180.

    Time frame: Day 1 to Day 180

  2. Phase II: Difference in Ventilator-Free Days within 28 Days Compared to Placebo

    To evaluate the efficacy of GKL-006RTU injection compared to placebo in participants with moderate-to-severe ARDS. The primary efficacy endpoint is the difference in ventilator-free days (days alive and free from mechanical ventilation) within 28 days post-treatment between the GKL-006RTU injection group and the placebo group.

    Time frame: Day 1 to Day 28

Secondary outcomes

  1. Phase I: All-cause Mortality at Day 1 to Day 28, Day 90, and Day 180

    To assess the all-cause mortality rate in participants treated with GKL-006RTU injection at Day 1 to Day 28, Day 90, and Day 180.

    Time frame: Day 1 to Day 28, Day 90, and Day 180

  2. Phase I: Ventilator-Free Days, ICU-Free Days, and Organ Support-Free Days within Day 1 to Day 28

    To evaluate the number of days alive and free from mechanical ventilation, intensive care unit (ICU) stay, and organ support from Day 1 to Day 28.

    Time frame: Day 1 to Day 28

  3. Phase I: Change in Arterial Partial Pressure of Oxygen/Fraction of Inspired Oxygen Ratio (PaO2/FiO2) from Baseline

    The ratio is calculated by dividing the arterial partial pressure of oxygen by the fraction of inspired oxygen. Measurements will be taken at baseline and various time points from Day 1 to Day 28.

    Time frame: Day 1 to Day 28

  4. Phase I: Change in Arterial Potential of Hydrogen (pH) from Baseline

    To evaluate the change in arterial pH from baseline at various time points from Day 1 to Day 28.

    Time frame: Day 1 to Day 28

  5. Phase I: Change in Arterial Partial Pressure of Oxygen (PaO2) from Baseline

    To evaluate the change in arterial partial pressure of oxygen (PaO2) from baseline at various time points from Day 1 to Day 28.

    Time frame: Day 1 to Day 28

  6. Phase I: Change in Arterial Partial Pressure of Carbon Dioxide (PaCO2) from Baseline.

    To evaluate the change in arterial partial pressure of carbon dioxide (PaCO2) from baseline at various time points from Day 1 to Day 28.

    Time frame: Day 1 to Day 28

  7. Phase I: Change in Arterial Lactate from Baseline

    To evaluate the change in arterial lactate levels from baseline at various time points from Day 1 to Day 28.

    Time frame: Day 1 to Day 28

  8. Phase I: Change in Sequential Organ Failure Assessment (SOFA)-2 Score from Baseline

    To evaluate the change in the Sequential Organ Failure Assessment (SOFA)-2 score from baseline. The SOFA-2 score ranges from 0 to 24, with higher scores indicating more severe organ dysfunction/failure. Assessments will be made at various time points from Day 1 to Day 28.

    Time frame: Day 1 to Day 28

  9. Phase II: Difference in All-cause Mortality Compared to Placebo at Day 7, Day 14, Day 28, Day 90, and Day 180

    To evaluate the difference in all-cause mortality between the GKL-006RTU injection group and the placebo group at Day 7, Day 14, Day 28, Day 90, and Day 180.

    Time frame: Day 7, Day 14, Day 28, Day 90, and Day 180

  10. Phase II: Difference in ICU-Free Days and Organ Support-Free Days Compared to Placebo within Day 1 to Day 28

    To evaluate the difference in days free from intensive care unit (ICU) stay and days free from organ support between the GKL-006RTU injection group and the placebo group from Day 1 to Day 28.

    Time frame: Day 1 to Day 28

  11. Phase II: Difference in Change of Arterial Partial Pressure of Oxygen/Fraction of Inspired Oxygen Ratio (PaO2/FiO2) Compared to Placebo

    To evaluate the difference in the change of the PaO2/FiO2 ratio from baseline between the GKL-006RTU injection group and the placebo group.

    Time frame: Day 1 to Day 28

  12. Phase II: Difference in Change of Arterial Potential of Hydrogen (pH) Compared to Placebo.

    To evaluate the difference in the change of arterial pH from baseline between the GKL-006RTU injection group and the placebo group.

    Time frame: Day 1 to Day 28

  13. Phase II: Difference in Change of Arterial Partial Pressure of Oxygen (PaO2) Compared to Placebo.

    To evaluate the difference in the change of arterial partial pressure of oxygen (PaO2) from baseline between the GKL-006RTU injection group and the placebo group.

    Time frame: Day 1 to Day 28

  14. Phase II: Difference in Change of Arterial Partial Pressure of Carbon Dioxide (PaCO2) Compared to Placebo

    To evaluate the difference in the change of arterial partial pressure of carbon dioxide (PaCO2) from baseline between the GKL-006RTU injection group and the placebo group.

    Time frame: Day 1 to Day 28

  15. Title: Phase II: Difference in Change of Arterial Lactate Compared to Placebo

    To evaluate the difference in the change of arterial lactate levels from baseline between the GKL-006RTU injection group and the placebo group.

    Time frame: Day 1 to Day 28

  16. Phase II: Difference in Change of Sequential Organ Failure Assessment (SOFA)-2 Score Compared to Placebo

    To evaluate the difference in the change of the Sequential Organ Failure Assessment (SOFA)-2 score from baseline between the GKL-006RTU injection group and the placebo group. The SOFA-2 score ranges from 0 to 24, with higher scores indicating more severe organ dysfunction or failure.

    Time frame: Day 1 to Day 28

  17. Phase II: Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 to Day 180

Other outcomes

  1. [Phase I & II] Immunogenicity Assessment: Anti-MHC Antibodies and Donor-Specific Antibodies (DSA)

    Detection of allogeneic antibodies against Major Histocompatibility Complex (MHC) Class I and Class II. If positive, the Mean Fluorescence Intensity (MFI) of Donor-Specific Antibodies (DSA) will be measured. This applies to both Phase I and Phase II cohorts.

    Time frame: Day 1, Day 14, Day 28, and Day 90

  2. [Phase I & II] Pharmacokinetics (PK): Count of Allogeneic Invariant Natural Killer T (iNKT) Cells

    Enumeration of allogeneic invariant natural killer T (iNKT) cells in peripheral blood post-treatment. This assessment is conducted in both Phase I and Phase II.

    Time frame: Day 1 to Day 4, Day 7, Day 14, Day 28, and Day 90

  3. [Phase I & II] Pharmacodynamics (PD): Inflammatory Cytokines and Acute Phase Reactants

    Measurement of changes in peripheral blood levels of: oC-reactive protein (CRP) oInterleukin-1 Receptor Antagonist (IL-1RA) oInterleukin-6 (IL-6) oInterleukin-8 (IL-8) oTumor Necrosis Factor-alpha (TNF-α) oInterferon-gamma (IFN-γ) Soluble Tumor Necrosis Factor Receptor 1 (sTNFr1)

    Time frame: Day 1, Day 4, Day 7, Day 14, Day 28, and Day 90

  4. [Phase I & II] Pharmacodynamics (PD): Serum Bicarbonate (HCO3-) Levels

    Measurement of changes in serum bicarbonate (HCO3-) levels in peripheral blood post-treatment for both Phase I and Phase II cohorts.

    Time frame: Day 1, Day 4, Day 7, Day 14, Day 28, and Day 90

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — There are no plans to share individual participant data at this time.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Dec 2028, 25 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: start Jul 2026 → Nov 2026, primary completion Jul 2027 → Dec 2028 and completion Jul 2027 → May 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2026
First posted
Jul 16, 2026
StartEst.
Nov 10, 2026was Jul 2026
Primary completionEst.
Dec 30, 2028was Jul 2027
CompletionEst.
May 30, 2029was Jul 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 10, 2026→Nov 10, 2026
Sep 30, 2026
Primary completion
Jul 30, 2027→Dec 30, 2028
Sep 30, 2026
Study completion
Jul 30, 2027→May 30, 2029
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Start date Jul 10, 2026→Nov 10, 2026
    Primary completion Jul 30, 2027→Dec 30, 2028
    Study completion Jul 30, 2027→May 30, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07706855
Responsible party
Sponsor
First posted
Jul 16, 2026
Start date
Nov 10, 2026 (estimated)
Primary completion
Dec 30, 2028 (estimated)
Completion
May 30, 2029 (estimated)
Last update
Sep 30, 2026

Study contacts

Bin Du, M.D.
Contact
dubin98@gmail.com
+86-10-69151188

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion